Clinical testing of EGFR tyrosine kinase inhibitors (TKIs) in advanced breast cancer patients demonstrated that EGFR TKIs are ineffective in treating this disease even though EGFR is overexpressed [5], [6]. The gene discussed is EGFR; the disease is breast cancer.